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Background: First-line chemotherapy regimens suitable for elderly advanced breast cancer patients
are still not defined.
Patients and methods: Women with stage III or IV breast cancer aged >_70 years were enrolled in a
phase II study aimed to evaluate both activity and toxicity of weekly paclitaxel. Among 46 planned
patients, at least 18 responses and not more than seven unacceptable toxic events are required for a
favourable conclusion. Paclitaxel 80 mg/m2 was administered weekly for 3 weeks every 28 days.
Results: Unacceptable toxicity occurred in seven out of 46 patients evaluated for toxicity [15.2%;
exact 95% confidence interval (CI) 7.6% to 28.2%] and was represented by one case of febrile
neutropenia, one case of severe allergic reaction and five cases of cardiac toxicity. Among 41 patients
evaluated for response, a complete response occurred in two (4.9%) patients and a partial response
in 20 (48.8%), with an overall response rate of 53.7% (exact 95% CI 38.7% to 67.9%). The median
progression-free survival was 9.7 months (95% CI 8.5–18.7) and median survival was 35.8 months
(95% CI 19–not defined).
Conclusions: Weekly paclitaxel is highly active in elderly advanced breast cancer patients. Data on
cardiovascular complications, however, indicate the need for a careful monitoring of cardiac func-
tion before and during chemotherapy.
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Introduction
Choosing chemotherapy regimens suitable for elderly patients
with metastatic breast cancer can be difficult because pharma-
cological changes associated with ageing, as well as the func-
tional status and the presence of comorbidities, may hamper
the use of many cytotoxic drugs.
The association of anthracyclines and taxanes is considered
a standard treatment [1] for metastatic breast cancer patients.
However, the use of anthracycline-containing regimens in
elderly patients can led to an excessively high incidence of
toxicity [2]. The use of monochemotherapy with active drugs
other than anthracyclines, such as paclitaxel, may be a strategy
that combines both activity and tolerability in elderly patients.
Paclitaxel administered on a weekly schedule at doses of
80–100 mg/m2 has been shown to be active and well tolerated
[3, 4]. Preliminary results of a direct comparison showed
superiority of weekly compared with every 3 weeks paclitaxel
in terms of response rate and time to progression [5]. Our pre-
vious dose-finding study showed that weekly paclitaxel can be
safely administered to elderly breast cancer patients [6].
Data suggesting high activity and low toxicity of weekly
paclitaxel prompted the present study evaluating the safety
and activity of weekly paclitaxel as first-line chemotherapy in
women >_70 years.
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Patients and methods
Eligibility criteria
Women with histologically or cytologically confirmed metastatic (stage
IV) or locally advanced (stage IIIA, IIIB) breast cancer, aged >_70 years,
and not previously treated with chemotherapy for their metastatic or
locally advanced disease were eligible. Previous adjuvant chemotherapy
not containing taxanes (paclitaxel or docetaxel) and prior endocrine
therapy were allowed. Other eligibility criteria were as follows: Eastern
Cooperative Oncology Group performance status of 0–2; absence of brain
metastases; adequate bone marrow (absolute granulocyte count >_1500ml,
platelets >_ 100 000ml), renal (serum creatinine less than or equal to the
upper normal limit) and liver [in the absence of liver metastases: total
bilirubin and aspartate aminotransferase (AST) and alanine aminotransfer-
ase (ALT) less than or equal to the upper normal limit; in the presence of
liver metastases: total bilirubin <_1.5 the upper normal limit and AST
and ALT <_ 2.5 the upper normal limit] functions, and presence of mea-
surable or non-measurable tumour lesions. Patients with non-measurable
disease were enrolled but they were a priori considered evaluable only for
toxicity, time to progression and overall survival and not for activity
(response rate). Patients with serious medical conditions potentially
compromising study participation were excluded. Pre-study evaluation
included a complete history and physical examination, complete blood
cell count with differential, platelet count, serum chemistries, ECG, multi-
gated acquisition (MUGA) or echocardiography, and tumour measure-
ment. All patients gave their written informed consent before study entry.
Geriatric assessment
At baseline a multidimensional geriatric assessment was performed as
described previously [7, 8]. Comorbidities were scored as absent/present
using a predefined list of 33 possible diseases; the Charlson score [9] was
then built by summing data regarding myocardial infarction, congestive
heart failure, peripheral vascular disease, cerebral vascular disease, demen-
tia, chronic pulmonary disease, connective tissue disease, ulcer disease,
mild liver disease and diabetes. The other pathological conditions hypoth-
esised in the Charlson score were not taken into account because they
were precluded by the exclusion criteria for the study. Geriatric scales,
namely those exploring activities of daily living (ADL) [10] and instru-
mental ADL (IADL) [11] were also used. Response codes range from 0
(full ability) to 8 (full disability) for the IADL scale and from 0 to 6 for
the ADL scale.
Study design and sample size
The study was designed as a multicentre, two-stage, phase II study with
activity and toxicity as primary end points [12]. The primary objective
was to evaluate the activity (response rate) and toxicity (within the first
four cycles) of weekly paclitaxel. The following parameters were con-
sidered for calculation of sample size: 30% as the lower acceptable
response rate, 50% as the auspicated response rate, 25% as the higher
acceptable rate of patients with unacceptable toxicity, 5% as the auspi-
cated rate of patients with unacceptable toxicity, 10% of risk of false-
negative result, 10% of risk of false-positive result for activity and 10% of
risk of false-positive result for toxicity.
With these requirements, the planned sample size was 22 patients for
the first stage and 46 at the end of the study, when at least 18 responses
and not more than seven unacceptable toxic events within the first four
cycles of chemotherapy were required for a favourable conclusion. The
first stage was considered to be successfully passed if at least eight
responses and not more than four unacceptable toxic events were observed.
The protocol was approved by the Protocol Review and the ethics commit-
tees of the National Cancer Research Institute of Genoa, Italy.
Treatment regimen
Paclitaxel 80 mg/m2 was administered intravenously over 1 h weekly for
3 weeks every 28 days. Premedications, given 30 to 60 min before chemo-
therapy, consisted of diphenhydramine 40 mg administered intramus-
cularly, dexamethasone 12 mg administered intravenously and ranitidine
150 mg administered intravenously. Treatment continued for a minimum
of four and a maximum of six cycles. Treatment was delayed for 1 week
for grade >_ 2 neutropenia and/or grade >_1 thrombocytopenia. No dose
reduction was planned by protocol. Treatment was interrupted if disease
progression or unacceptable toxicity occurred. The use of granulocyte
colony-stimulating factor was allowed in the presence of an absolute
granulocyte count <1000/mm3.
Assessment of response
According to RECIST (Response Evaluation Criteria in Solid Tumors)
guidelines, tumour lesions were categorised as measurable if they
could be accurately measured in at least one dimension as >_ 20 mm
with conventional techniques or as >_ 10 mm with spiral computed
tomography. All other tumour lesions, including small lesions and
truly non-measurable lesions, were categorised as non-measurable
lesions [13]. Tumour measurements for response assessment were
obtained every two cycles. Response evaluation was performed accord-
ing to RECIST guidelines.
Assessment of toxicity
Complete blood cell count, platelet count and toxicity assessment were
performed weekly, with performance status, serum chemistry and ECG
assessed before each cycle. Echocardiography or MUGA with the evalu-
ation of left ventricular ejection fraction was performed at baseline and
every two cycles. Toxicity was evaluated according to the National Can-
cer Institute Common Toxicity Criteria, version 2.0.
Unacceptable toxicity, requiring interruption of the treatment at the
planned dose of 80 mg/m2, was defined by the occurrence within the first
four cycles of chemotherapy, of at least one of the following events: grade
>_ 3 thrombocytopenia (platelets <_50 000ml); grade 3 or 4 anemia (hemo-
globin <8 g/dl); grade 4 vomiting or mucositis, or diarrhoea or consti-
pation; organ toxicity of grade >_ 2, excluding alopecia and neurotoxicity;
toxicity of any grade that worsened general conditions thus hampering
tumour assessment after two cycles.
Statistical methods
For response rate and unacceptable toxicity rate, exact 95% confidence
intervals (CIs) were calculated. Time to progression was defined as the
time elapsed from beginning of treatment to the date of documented dis-
ease progression, the date of death without progression or the date of the
last visit for patients who had not yet progressed at the end of the study.
Survival was defined as the time elapsed from beginning of treatment to
the date of death or the date of the last visit for patients alive at the end of
the study. Two patients who were lost immediately after registration and
never starting chemotherapy were censored at time zero. Unplanned sub-
group analyses were performed to generate hypotheses regarding the
possibility that baseline geriatric assessment could help to predict toxicity
or efficacy of treatment. Associations between Charlson index, ADL and
IADL scores (all transformed in dichotomic variables), response rate and
unacceptable toxicity rate were studied by contingency tables analysed by
Fisher’s exact test. Progression-free survival curves within the same sub-
groups were compared using the log-rank test. All analyses were per-
formed using S-PLUS 6.0 Professional Release 1 (Insightful Corporation,
Seattle, WA, USA).
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Results
From May 2000 to June 2001, 23 patients were enrolled; one
was not eligible because of prior chemotherapy for metastatic
disease. Among 22 eligible patients there were 13 objective
responses and four episodes of unacceptable toxicity. Thus the
enrolment was continued. By March 2003, 48 eligible patients
had been enrolled by seven participating centres. The main
baseline characteristics are listed in Table 1. Presence of
comorbidities at baseline was assessed in 41 patients, and
hypertension, arthrosis-arthritis, osteoporosis, arrhythmias and
peripheral vascular disease were the most common comor-
bidities (Table 2). Based on comorbidity data, 26 patients
(63.4%) had none of the diseases used for the calculation of
the Charlson scale (Charlson index 0). Baseline ADL and
IADL data were available for 38 and 36 patients, respectively;
at least one ADL dependency was reported in 10 (26.3%)
patients and IADL dependency in at least one item was
reported in 25 (73.2%) patients.
Treatment compliance
Two patients never started chemotherapy, one who was lost
immediately after enrolment and one who developed heart
failure after registration and before the first planned day of
treatment; these two patients are not accounted for in compli-
ance description. Among the 46 patients actually treated, the
median number of administered cycles was six (range one to
six); 24 (52.2%) patients received six cycles and 35 (76.1%)
received four or more cycles. Treatment was interrupted for
reasons other than protocol completion in 15 patients (32.6%),
namely for progression (eight cases) and toxicity (seven cases
including two toxic deaths). Median delivered dose-intensity
was 56 mg/m2/week, which is 93% of that planned; 34 patients
(73.9%) received at least 80% of the planned dose-intensity.
Table 1. Patient characteristics
Characteristic
Overall number 48
Age (years)
Median 74
Range 70–87
ECOG performance status [n (%)]
0 25 (52.1)
1 19 (39.6)
2 4 (8.3)
Stage [n (%)]
IIIA/IIIB 9 (18.7)
IV 39 (81.3)
Previous therapy for early breast cancer [n (%)]
None (stage IIIA/IIIB) 9 (18.7)
None (presenting as stage IV) 8 (16.7)
Neoadjuvant chemotherapy 4 (8.3)
Surgery 31 (64.6)
Radiotherapy 13 (27.1)
Adjuvant chemotherapy 20 (41.7)
Adjuvant endocrine therapy 18 (37.5)
Prior therapy for metastasis [n (%)]
None 35 (72.9)
Radiotherapy alone 1 (2.1)
Endocrine therapy 12 (25.0)
No. of target lesions [n (%)]
0 (not evaluable for response) 7 (14.6)
1 27 (56.3)
2 9 (18.7)
>2 5 (10.4)
Overall no. of metastatic sites [n (%)]
1 10 (20.8)
2 17 (35.4)
>2 21 (43.8)
ECOG, Eastern Cooperative Oncology Group.
Table 2. Main comorbidities
Type of comorbidity n (%)
Cardiovascular diseases
Hypertension 26 (63.4)
Previous myocardial infarction 2 (4.9)
Ischemic disease 2 (4.9)
Arrhythmia 7 (17.1)
Peripheral vascular disease 6 (14.6)
Lung diseases
Chronic obstructive pulmonary disease 1 (2.4)
Other lung disease 1 (2.4)
Digestive diseases
Peptic ulcer 1 (2.4)
Gastritis 5 (12.2)
Cholelithiasis 4 (9.8)
Chronic epatopathy 1 (2.4)
Other digestive diseases 1 (2.4)
Kidney/urinary diseases
Renal calculi 3 (7.3)
Urinary incontinence 3 (7.3)
Osteoarticular diseases
Arthrosis/arthritis 15 (36.6)
Osteoporosis 12 (29.3)
Other osteoarticular diseases 4 (9.8)
Depression 5 (12.2)
Skin diseases 2 (4.9)
Endocrine/dismetabolic diseases
Diabetes 3 (7.3)
Other endocrine/dismetabolic diseases 2 (4.9)
Other 1 (2.4)
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Toxicity
All 46 patients who received at least one administration of
chemotherapy were evaluated for toxicity. Unacceptable tox-
icity (Table 3) within the first four cycles occurred in seven
patients (15.2%; exact 95% CI 7.6% to 28.2%) and was rep-
resented by one case of febrile neutropenia associated with
lung infiltrates, one case of severe allergic reaction and five
cases of cardiac toxicity, including two patients who died, one
with pulmonary embolism 2 days after chemotherapy (third
cycle) and one with congestive heart failure 26 days after
administration of the second cycle.
Worst grade toxicities observed across the whole treatment
period are reported in Table 4. Two additional cases of severe
cardiotoxicity (one case of grade 2 and one of grade 3)
occurred after the fifth cycle. Clinically relevant hematological
toxicity was uncommon, with two cases of febrile neutropenia
(including the one considered as unacceptable according to
study design), one of grade 4 neutropenia, one of grade 3
thrombocytopenia and one of grade 3 anemia. This grade 3
anemia was present at baseline and was not considered as
unacceptable toxicity. Grade >_2 sensorial neuropathy occurred
in 33% of patients. One patient, with concomitant cholelithi-
asis, had an increase in gamma-glutamyl transpeptidase value
that was classified as grade 3 liver toxicity.
Activity
Seven patients, including the patient who was lost immedi-
ately, were not eligible for response assessment because of a
lack of target lesions at baseline. As reported in Table 5, out
of the remaining 41 patients, three were not actually evaluated
for response and were considered as non-responders. A com-
plete response occurred in two (4.9%) patients and a partial
response in 20 (48.8%), with an overall response rate of
53.7% (exact 95% CI 38.7% to 67.9%); 11 patients (26.8%)
had disease stabilisation. Among the nine patients with locally
advanced breast cancer there were eight partial responses
(response rate 88.9%; exact 95% CI 56.5% to 99.4%) and one
stable disease. Among 32 patients with stage IV disease, there
were two complete and 12 partial responses, for a response
rate of 43.8% (exact 95% CI 28.2% to 60.7%).
Time to progression and overall survival
At the time of this analysis (March 2003), out of 39 patients
with stage IV disease, 28 (71.8%) had suffered progression
Table 4. Worst toxicity reported in 46 evaluable patients
Type NCI CTC grade (% of patientsa)
0 1 2 3 4 5
Allergy 40 (87.0) 5 (10.9) – – 1 (2.2)
Anemia 24 (52.2) 18 (39.1) 3 (6.6) 1 (2.2) – –
Neutropenia 36 (78.3) 2 (4.3) 4 (8.7) 3 (6.6) 1 (2.2)
Febrile neutropenia 44 (95.7) 2 (4.3) – –
Thrombocytopenia 44 (95.7) 1 (2.2) – 1 (2.2) – –
Cardiovascular 34 (73.9) 5 (10.9) 3 (6.6) 1 (2.2) 1 (2.2) 2 (4.3)
Fatigue 9 (19.6) 15 (32.6) 20 (43.5) 2 (4.3) – –
Alopecia 6 (13.0) 24 (52.2) 16 (34.8)
Constipation 30 (65.2) 13 (28.3) 2 (4.3) 1 (2.2) – –
Diarrhoea 34 (73.9) 10 (21.7) 2 (4.3) – – –
Nausea 27 (58.7) 7 (15.2) 10 (21.7) 2 (4.3) – –
Vomiting 32 (69.6) 8 (17.4) 6 (13.0) – – –
Liver 45 (97.8) – – 1 (2.2) – –
Neuropathy motor 44 (95.7) 2 (4.3) – – – –
Neuropathy sensor 24 (52.2) 7 (15.2) 14 (30.4) 1 (2.2) – –
aBecause of rounding, percentages do not sum up to 100.
NCI CTC, National Cancer Institute Common Toxicity Criteria.
Table 5. Objective response according to RECIST
n (%) Exact 95% CI
All eligible patients (n = 41)
Responding 22 (53.7) 38.7–67.9
Complete response 2 (4.9)
Partial response 20 (48.8)
Non-responding 19 (46.3)
Stable disease 11 (26.8)
Progressive disease 5 (12.2)
Not evaluateda 3 (7.3)
Patients with stage IV disease (n = 32)
Responding 14 (43.8) 28.2–60.7
Non-responding 18 (56.2)
Patients with stage III disease (n = 9)
Responding 8 (88.9) 56.5–99.4
Non-responding 1 (11.1)
aTwo cases never started chemotherapy (one lost and one for decline of
cardiac function after enrolment); one case not restaged at proper time
for response assessment.
RECIST, Response Evaluation Criteria in Solid Tumors; CI, confidence
interval.
Table 3. Details of unacceptable toxicity
Type of toxicity (time) Number of
cases
Cardiovascular grade 5
Congestive heart failure (26 days after day 1, cycle 2) 1
Pulmonary embolism (2 days after day 15, cycle 3) 1
Cardiovascular grade 4 + thrombocytopenia grade 3
Acute myocardial infarction (7 days after day 1, cycle 2) 1
Cardiovascular grade 2
Resting ejection fraction reduced by 27% (after cycle 2) 1
Resting ejection fraction reduced by 24% (after cycle 4) 1
Febrile neutropenia
Associated with lung infiltrates, dyspnea, disoriented
to time and place (7 days after day 8, cycle 3)
1
Allergic reaction grade 4 (day 1, cycle 1) 1
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and 15 had died. Median progression-free survival was
9.7 months (95% CI 8.5–18.7) and median survival was
35.8 months (95% CI 19–not defined). Among nine patients
with locally advanced breast cancer, one patient died of pul-
monary embolism during treatment and another progressed
6 months from the beginning of treatment and died 1 month
later; seven patients are disease-free after a median follow-up
of 14 months.
Predictive value of geriatric scales
Unplanned subgroup analyses were performed to generate
hypotheses regarding the possibility that geriatric assessment
can help to predict toxicity and activity of treatment. The
Charlson and the IADL scales were never predictive of either
toxicity or activity. On the contrary, the presence of at least one
inability among those itemised in the ADL scale was signifi-
cantly associated with both a lower probability of response
(P=0.009, Fisher’s exact test) and a shorter progression-free
survival (P=0.04, log-rank test), but not with unacceptable tox-
icity rates.
Discussion
A major question faced by oncologists treating older patients
with chemotherapy is the selection of regimens with a
favourable balance between toxicity and activity, particularly
in the palliative setting. Prediction of toxicity and activity in
the elderly is very difficult. Compared with younger patients,
the elderly are generally at increased risk of developing che-
motherapy-induced toxicity, such as cardiotoxicity [14, 15],
myelodepression [16, 17] and mucositis [18, 19]. Therefore,
the toxicity profile of the majority of cytotoxic drugs may be
different and sometimes unpredictable in elderly patients.
This phase II trial focused exclusively on elderly patients
and its design took into account both toxicity and activity as
criteria for recommendation about the treatment with weekly
paclitaxel. We planned to consider weekly paclitaxel clinically
interesting and useful for future metastatic breast cancer trials
in the elderly if no more than 25% and possibly only 5% of
patients experienced unacceptable toxicity, and if not less than
30% and possibly 50% of patients obtained an objective
response. The actual figures we observed in the study were
15% unacceptable toxicity and 54% objective response; there-
fore, on the basis of our premise weekly paclitaxel can be con-
sidered a useful regimen for elderly advanced breast cancer
patients. Notably, there was a relevant rate of unacceptable
cardiovascular toxicity (five patients) ranging from grade 2 to 5.
Two patients had a decrease in resting ejection fraction, one
patient had acute myocardial infarction and two patients had
fatal cardiovascular toxicity consisting of congestive heart
failure (one patient) and pulmonary embolism (one patient).
Two additional patients developed severe cardiotoxicity (one
grade 2 and one grade 3) after the fifth cycle. In addition,
grade 1 cardiotoxicity (i.e. asymptomatic decline of resting
ejection fraction >_10% but <_20% of baseline value) was
observed in five patients (11%). Overall, cardiotoxicity of any
grade developed in 12 patients (26%). Specifically, grade 5, 4,
3, 2 and 1 cardiotoxicity occurred in two (4%), one (2%), one
(2%), three (7%) and five (11%) patients, respectively. No
cases of cardiotoxicity were observed in previous studies with
weekly paclitaxel administered in metastatic breast cancer
patients [3, 4]. The different profile of cardiotoxicity observed
in our study may have various explanations. The majority of
the events (eight out of 12; 67%) were grade 1 (five cases)
and grade 2 (three cases) cardiotoxicity, i.e. laboratory decline
of resting ejection fraction without clinical symptoms. These
events were recorded because a routine MUGA or echocardio-
graphic evaluation was performed in our study every two
cycles. In the previous studies such a routine monitoring of
cardiac function was not carried out, so such a toxicity could
not be recorded. The 9% incidence of clinically overt cardio-
toxic events observed in our study and not previously
described may be related to the higher risk of cardiotoxicity of
our patients as compared with patients treated in other studies.
A major risk of developing cardiotoxicity is older age: the
median age of our patients was 74 years (range 70–87) com-
pared with a mean age of 60 years (range 31–88) reported in
the study by Perez et al. [4] and a median age of 57 years
(range 35–74) in the study by Seidman et al. [3]. Moreover
other cardiotoxicity risk factors, such as hypertension, were
present in up to 63% of our patients. Such differences in
patients’ characteristics, mainly related to the enrolment in our
study of true elderly patients, may explain the difference in
cardiotoxicity and strongly indicate that results in terms of
toxicity from studies performed in young patients cannot auto-
matically be transferred to elderly patients.
The mortality rate (4%) during chemotherapy observed in
our study is similar to that reported in the study by Chen et al.
[20], where 5% of 59 elderly patients died after starting
chemotherapy. Cardiovascular complications, in particular,
were also the main cause of death in clinical trials on elderly
patients not receiving chemotherapy. Castiglione et al. [21]
reported 2% of cardiovascular mortality in breast cancer
elderly patients undergoing adjuvant endocrine therapy with
tamoxifen and prednisone for 1 year.
We observed a response rate of 54% in the overall popu-
lation (stage III plus stage IV) and of 44% in stage IV
patients. This percentage is similar to that recently reported
with weekly paclitaxel in a phase III study not focused on
elderly patients, i.e. 40% [5]. On the other hand, the activity
observed in our study is higher than that obtained in other
studies in which elderly metastatic breast cancer patients were
treated with monochemotherapy with drugs such as docetaxel
(response rate 25%) [22], doxifluoridine (27%) [23], mitoxan-
trone (25%) [24], vinorelbine (38%) [25] and capecitabine
(36%) [26]. Moreover, a clinically very interesting long
progression-free survival (9.7 months) and overall survival
(36 months) were observed in this setting of metastatic breast
cancer patients.
Our data indicate that weekly paclitaxel is a highly active
treatment in elderly patients with advanced breast cancer.
Data on cardiovascular complications, however, indicate
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the need for careful monitoring of cardiac function before and
during chemotherapy.
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